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Introduction
Human papillomavirus (HPV) has an important role in the development of cervical intraepithelial neoplasia (CIN) and cervical carcinoma. However, compared with the high rates of HPV infections in women without cervical neoplasia, the occurrence of CIN and cervical cancer is rare. 1 The search for risk factors for cervical neoplasia, other than HPV, is therefore still ongoing. A candidate risk factor is Chlamydia trachomatis. Case-control studies have reported that serum antibodies against C trachomatis are relatively more frequent in women with CIN or cervical carcinoma compared with controls. [2] [3] [4] [5] [6] [7] In the present study we explored the hypothesis that the presence of C trachomatis antibodies is associated with the severity of neoplastic lesions using a cross sectional study design. An (unexpected) high prevalence of antichlamydial antibodies in women with (micro)invasive carcinoma ((M)IC) was found. This high prevalence of antichlamydial antibodies in women with (M)IC and a higher prevalence in women with (M)IC than in women with CIN III was not reported previously. [2] [3] [4] [5] [6] [7] Therefore, a second study population was selected in an attempt to confirm our results.
Methods
PATIENTS
Two groups of women referred for an abnormal Papanicolaou smear to the gynaecological outpatient clinic of the University Hospital Groningen, Netherlands, were recruited for this study. Group A comprised 296 women referred between September 1988 and September 1993 8 Blood samples were taken at the enrolment visit of all women. Periodate treated enzyme immunoassays (EIA) were carried out as described previously. 9 10 Treatment with sodium periodate results in enhanced specificity of the assay compared with the native EIA. 9 10 For both groups of patients, the same reference serum was used ensuring comparability of the results.
MORPHOLOGICAL EXAMINATION
Colposcopically directed biopsies were taken and graded according to the criteria of the World Health Organization. 11 If CIN was diagnosed, except for CIN I in group B, the whole transformation zone was subsequently excised by loop electrosection (LETZ) or cold knife conisation. Cervical neoplasia was classified according to the most severe histological lesion found.
Results
In group A 114 (39%) of 296 women tested positive for serum antibodies against C trachomatis. The prevalence of antichlamydial antibodies did not increase significantly with increasing severity of CIN. However, the prevalence of C trachomatis antibodies was significantly higher in the group of women with (M)IC than in women with CIN (table 1) .
Patient characteristics in group B met the characteristics of group A apart from the proportion of women diagnosed with no dysplasia or CIN II, for which the 95% confidence intervals did not overlap (table 2) . Serum antibodies against C trachomatis were found in 164 (50%) of 331 women in group B. No increasing trend was observed for the proportion of women positive for antichlamydial antibodies with increasing severity of CIN (table 1). The prevalence of C trachomatis antibodies in women with (M)IC was not significantly higher than in women with CIN.
Discussion
DiVerences between groups A and B might occur because of systematic diVerences between the two groups or because of chance. EVort was made to reduce systematic diVerences: periodate treated EIA was performed for both groups separately, but the same reference serum was used. Criteria for eligibility for group A and group B corresponded. We therefore have no other explanation than that the diVerence in the proportion of women with no dysplasia and CIN II is due to chance. The reported diVerences appeared to have no implication for our results.
Overall prevalences of antichlamydial antibodies were comparable for groups A and B. However, 93% of the women with (M)IC in group A had antichlamydial antibodies compared with 55% in group B. Prevalences reported by others are comparable with the prevalence found in group B. [2] [3] [4] [5] [6] [7] The number of women with (M)IC in group A is low. The 95% CI of the prevalence is very wide in this group and overlaps the 95% CI of the proportion observed in the same category of group B (table 2) . Chance has a great eVect on small study populations. 12 Considering what is discussed above we conclude that the high prevalence in the (M)IC group of A is due to chance.
The role of C trachomatis in the aetiology of cervical neoplasia is hard to interpret. Many studies reported antichlamydial antibodies to be more frequent in women with cervical neoplasia than in controls. [2] [3] [4] [5] [6] [7] This might indicate that C trachomatis has a causal role in cervical carcinogenesis. Our results suggest that C trachomatis does not favour the progression from CIN to invasive disease. However, it should be kept in mind that these serological data can not exclude the possible involvement of local factors induced by (chronic) C trachomatis infections.
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